**(See the Editorial Commentary by Harris on pages 2057--8.)**

Prevalence of drug resistance has increased steadily resulting in the need for safe and effective antibiotic treatment options, particularly for multidrug-resistant (MDR) Gram-negative bacteria \[[@CIT0001]\]. As rates of serious infections intensify, clinicians are forced to use agents of last resort or agents associated with toxicity (eg, polymyxins, aminoglycosides). Although some new β-lactam agents with activity against MDR pathogens have recently received Food and Drug Administration (FDA) approval, there is a need for additional options with differentiated mechanisms of action (MOAs) that are safe and effective. Alternatives to β-lactams are needed due to class-associated safety concerns (eg, hypersensitivity) and/or rapidly emerging resistance \[[@CIT0002]\].

ZTI-01 (fosfomycin for injection) is an injectable epoxide and sole antibiotic class member. The differentiated MOA inhibits an early step in peptidoglycan biosynthesis by covalently binding to MurA \[[@CIT0003]\]. In in vitro studies, ZTI-01 has demonstrated a broad spectrum of activity against a variety of clinically important MDR Gram-negative pathogens (including extended-spectrum beta-lactamase \[ESBL\]-producing Enterobacteriaceae and carbapenem-resistant Enterobacteriaceae \[CRE\]) and Gram-positive pathogens (including methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci) \[[@CIT0004]\].

In the United States, a tromethamine salt of fosfomycin is available, administered as a single 3-gram oral sachet indicated for treatment of uncomplicated urinary tract infection (UTI, ie, cystitis) \[[@CIT0005]\]. For more serious infections, oral administration provides inadequate concentrations due to its limited bioavailability (37%) and dose-limiting gastrointestinal tolerability \[[@CIT0005]\].

Outside the United States, intravenous (IV) fosfomycin, as evidenced in \>40 years of use in more than 60 clinical studies, has provided a safe and effective treatment option for patients with a variety of infections, often severe (ie, complicated UTI \[cUTI\], bacteremia, acute osteomyelitis, nosocomial pneumonia, surgical site infections, bone and joint infections, endocarditis, complicated skin infections, and bacterial meningitis) \[[@CIT0003], [@CIT0006]\]. Fosfomycin retains high in vitro activity with low and stable resistance despite longevity of use.

ZTI-01 is being developed for treatment of cUTI/acute pyelonephritis (AP) in the United States. This report presents the efficacy and safety results from the ZEUS trial, a multicenter, randomized, double-blind, phase 2/3 trial designed to evaluate safety and efficacy of ZTI-01 in treating hospitalized adults with cUTI/AP versus piperacillin-tazobactam (PIP-TAZ).

METHODS {#s1}
=======

Objectives {#s2}
----------

The primary objective was to demonstrate noninferiority (NI) of ZTI-01 to PIP-TAZ in overall success (clinical cure and microbiologic eradication) in microbiologic modified intent-to-treat (m-MITT) population at test of cure (TOC, day 19--21). Secondary objectives were to compare: (1) clinical cure rates in the 2 treatment groups in MITT, m-MITT, clinical evaluable (CE), and microbiologic evaluable (ME) populations at TOC, and (2) microbiological eradication rates in m-MITT and ME populations at TOC.

Study Design and Participants {#s3}
-----------------------------

ZEUS was a multicenter, randomized, parallel-group, double-blind phase 2/3 trial designed to evaluate safety, tolerability, efficacy, and pharmacokinetics of ZTI-01 in treating hospitalized adults with cUTI/AP versus PIP-TAZ at 92 global sites in 16 countries ([Figure 1](#F1){ref-type="fig"}).

![Study design. N: Number of patients in the ITT population. Percentages were calculated using the number of patients in the ITT population as the denominator. *A*, Completed study drug was defined as completing 7 to 14 days of treatment. *B*, Only included patients who received study drug. Patient 1401--16 had an adverse event and did not receive study drug. Abbreviations: ITT, intent-to-treat; LFU, late follow-up; PIP-TAZ, piperacillin-tazobactam; TOC, test of cure; ZTI-01, fosfomycin for injection.](ciz181f0001){#F1}

Patients provided written informed consent. The study was conducted according to the International Conference on Harmonisation Good Clinical Practice guidelines, Directive 2001/20/EC, applicable regulatory requirements, and the Declaration of Helsinki \[[@CIT0007]\]. Protocol was approved by local health agencies, study sites' independent ethics committees, and/or institutional review boards (clinicaltrials.gov NCT02753946). An independent, blinded, data monitoring committee assessed ZTI-01 safety and baseline evaluability for sample size adjustment (m-MITT).

The [Supplementary Appendix](#sup1){ref-type="supplementary-material"} lists full inclusion/exclusion criteria.

Randomization and Masking {#s4}
-------------------------

Eligible patients were randomized 1:1 to receive either 6 g ZTI-01 infused over 60 minutes every 8 hours \[q8h\] or 4.5 g PIP-TAZ (4 g PIP/0.5 g TAZ) infused over 60 minutes q8h. The PIP-TAZ dosage was based on labeled guidelines for cUTI/AP in the current Summary of Medicinal Product Characteristics \[[@CIT0008]\], with no dosage adjustment necessary. ZTI-01 doses were adjusted for patients with CrCl \<50 and ≥20 mL/min ([Supplementary Appendix](#sup1){ref-type="supplementary-material"}). Subjects with baseline CrCl \<20 mL/min were excluded from the study. Randomization was stratified by region (US vs Rest of World), baseline diagnosis (cUTI vs AP), and prior antibiotic therapy (single dose of short-acting antibiotic vs no prior antibiotic therapy). At least 30% of patients were intended to have a diagnosis of AP at study entry.

Patients received ZTI-01 and PIP-TAZ as 1-hour infusions 3 times daily for a fixed 7 days, except in patients with concurrent bacteremia who could receive up to 14 days at the investigator's discretion. Oral step-down therapy was prohibited.

Study Procedures {#s5}
----------------

Procedures included baseline urine collection for quantitative culture and blood cultures. Routine monitoring occurred for signs and symptoms of cUTI/AP and adverse events (AEs), and prespecified collection of laboratory data including chemistry panels, complete blood counts, and urine/blood cultures ([Supplementary Appendix](#sup1){ref-type="supplementary-material"}).

Baseline urine cultures growing ≥10^5^ colony-forming units (CFU)/mL and any positive blood cultures were sent to the central laboratory (JMI Laboratories, North Liberty, Iowa) for identification, quantification, susceptibility testing, and further characterization of the organism(s). Fosfomycin minimum inhibitory concentrations (MICs) were determined at a central lab using the agar dilution reference method.

Efficacy Endpoints {#s6}
------------------

Primary endpoint of overall success was a composite of investigators' determination of clinical cure (complete resolution or significant improvement of signs and symptoms such that no further antimicrobial therapy is warranted) plus microbiologic eradication (baseline pathogen was reduced to \<10^4^ CFU/mL on urine culture and if applicable, negative on repeat blood culture) in the m-MITT at TOC. Subjects with any missing postbaseline urine sample were classified as indeterminates, and conservatively deemed as failures in overall success analysis. Secondary efficacy endpoints included proportion of patients with clinical cure in MITT, m-MITT, and CE, and ME groups at TOC, and proportion of patients with microbiologic eradication in m-MITT and ME groups at TOC.

Pathogens isolated from patients who had a baseline and TOC pathogen underwent blinded, post hoc, pulsed-field gel electrophoresis (PFGE) typing. Microbiologic outcome was defined utilizing PFGE results whereby microbiologic persistence required the same genus and species of baseline and postbaseline pathogens as well as PFGE-confirmed genetic identity.

Phenotypic Resistance {#s7}
---------------------

Using MICs, blood or urine pathogens resistant to other antibiotic classes were categorized as: ESBL production (aztreonam, ceftazidime, or ceftriaxone MIC ≥2 µg/mL), CRE (imipenem or meropenem MIC ≥4 µg/mL), aminoglycoside resistance (gentamicin ≥8 µg/mL or amikacin ≥32 µg/mL), or MDR (nonsusceptibility to ≥3 antibiotic classes). Patients with multiple organisms of the same phenotype were counted only once.

Safety {#s8}
------

Patients who received any amount of study drug were included in the safety population. Safety endpoints included assessment of treatment-emergent AEs (TEAEs) and evaluation of changes from baseline in laboratory test results, ECGs and vital signs. AEs were coded using version 19.0 of Medical Dictionary for Regulatory Activities (MedDRA). Hy's law was defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 × upper limit of normal (ULN), alkaline phosphatase (ALP) ≤2 × ULN, and total bilirubin \>2 × ULN.

Statistical Analyses {#s9}
--------------------

Sample size of 230 patients per arm (N = 460) was based on FDA-agreed upon 15% NI margin, 70% predicted evaluability rate, 70% overall success rate in both treatment groups, 80% power, and 1-sided α = 0.025. Number and percentage of patients in each treatment group with an overall success, failure, and indeterminate response (ie, patients with missing data) were determined and response rate for the primary analysis was defined as the number of successes divided by the number of success, failure, and indeterminate. A 2-sided 95% confidence interval (CI) for the observed difference in overall success rate (ZTI-01 group minus PIP-TAZ group) was calculated using a continuity-corrected Z-statistic. Noninferiority of ZTI-01 to PIP-TAZ determined if the lower limit of the 95% CI for the difference in the m-MITT was \>−15%. Analyses were performed using SAS version 9.1 or higher (SAS Institute, Cary, North Carolina).

RESULTS {#s10}
=======

Patients {#s11}
--------

Patients (N = 465) were included between May 2016 and January 2017; 464 patients received ≥1 dose of study drug ([Figure 2](#F2){ref-type="fig"}). Patient demographics and baseline characteristics were well matched between treatment groups ([Table 1](#T1){ref-type="table"}, [Figure 2](#F2){ref-type="fig"}). Very few patients received prior antibiotics to treat their current cUTI/AP.

###### 

Patient Demographics: Primary Analysis Population (Microbiologic Modified Intent-to-Treat)

  --------------------------------------------------------------------------------------------------------
                                                             ZTI-01\                PIP-TAZ\
                                                             (N = 184)              (N = 178)
  ---------------------------------------------------------- ---------------------- ----------------------
  Age, y, mean (SD)                                          49.9 (20.92)           51.3 (20.71)

   Sex, n (%), Female:Male                                   119 (64.7):65 (35.3)   111 (62.4):67 (37.6)

  Race                                                                              

   White                                                     184 (100)              178 (100)

  BMI, kg/m^2^, mean (SD)                                    25.75 (5.26)           26.64 (5.84)

  Primary diagnosis                                                                 

   AP                                                        100 (54.3)             96 (53.9)

   cUTI                                                      84 (45.7)              82 (46.1)

  SIRS at baseline                                           62 (33.7)              52 (29.2)

  Bacteremia at baseline                                     19 (10.3)              13 (7.3)

  Estimated Charlson comorbidity index, mean (SD)            2.2 (2.63)             2.5 (2.93)

  CrCl, mL/min, mean (SD)                                    83.6 (32.85)           84.7 (32.25)

  CrCl, ≥20--50 mL/min                                       26 (14.1)              20 (11.2)

  Baseline pathogen                                                                 

  No prior short acting antibiotics                          168 (91.3)             169 (94.9%)

  Gram-negative Enterobacteriaceae                           177 (96.2)             169 (94.9)

   *Escherichia coli*                                        133 (72.3)             133 (74.7)

   *Klebsiella pneumonia*                                    27 (14.7)              25 (14.0)

   *Enterobacter cloacae* species complex                    9 (4.9)                3 (1.7)

   *Proteus mirabilis*                                       9 (4.9)                5 (2.8)

   *Klebsiella oxytoca*                                      3 (1.6)                2 (1.1)

   *Citrobacter amalonaticus/farmeri*                        1 (0.5)                0

   *Raoultella ornithinolytica*                              1 (0.5)                1 (0.6)

   *Serratia marcescens*                                     1 (0.5)                1 (0.6)

   *Morganella morganii*                                     0                      1 (0.6)

  Gram-negative aerobes other than Enterobacteriaceae        10 (5.4)               9 (5.1)

   *Pseudomonas aeruginosa*                                  8 (4.3)                9 (5.1)

   *Acinetobacter baumannii-calcoaceticus* species complex   2 (1.1)                0

  Gram-positive aerobes                                      4 (2.2)                8 (4.5)

   *Enterococcus faecalis*                                   3 (1.6)                7 (3.9)

   *Staphylococcus aureus*                                   1 (0.5)                0

   *Staphylococcus saprophyticus*                            0                      1 (0.6)
  --------------------------------------------------------------------------------------------------------

The data represent n (%) unless otherwise specified.

Abbreviations: AP, acute pyelonephritis; BMI, body mass index; CrCl, creatinine clearance; cUTI, complicated urinary tract infection; PIP-TAZ, piperacillin-tazobactam; SD, standard deviation; SIRS, systemic inflammatory response syndrome; ZTI-01, fosfomycin for injection.

![Analysis population disposition. Percentages were calculated using the number of patients in the ITT population as the denominator. Abbreviations: CE, clinical evaluable; CFU, colony-forming unit; EOT, end of treatment; I/E, inclusion/exclusion; ITT, intent-to-treat; LFU, late follow-up; ME, microbiologic evaluable; MITT, modified intent to treat; m-MITT, microbiologic modified intent to treat; PIP-TAZ, piperacillin-tazobactam; TOC, test of cure; ZTI-01, fosfomycin for injection.](ciz181f0002){#F2}

Treatment {#s12}
---------

Median durations of IV therapy (safety population) were 7.1 days for both ZTI-01 and PIP-TAZ; 5/233 (2.1%) and 6/231 (2.6%) of patients in the ZTI-01 and PIP-TAZ groups, respectively, received 11--14 days of treatment for bacteremic cUTI/AP.

Primary Efficacy {#s13}
----------------

ZTI-01 was noninferior to PIP-TAZ for the primary efficacy outcome of overall success (clinical cure and microbiologic eradication) at TOC (m-MITT). Overall success occurred in 64.7% of ZTI-01 patients and 54.5% of PIP-TAZ patients (treatment difference 10.2%, 95% CI \[−0.4, 20.8\]) ([Table 2](#T2){ref-type="table"}).

###### 

Overall, Clinical, and Microbiological Response by Analysis Populations

                                                             Without PFGE (Uropathogen Identity Based on Species Name)   With PFGE (post hoc analysis) (Uropathogen I dentity Based on Molecular Typing)                                                   
  ---------------------------------------------------------- ----------------------------------------------------------- --------------------------------------------------------------------------------- --------------------- ------------ ------------ ---------------------
  TOC (m-MITT)                                                                                                                                                                                                                                             
  Primary endpoint---overall response                                                                                                                                                                                                                      
  N                                                          184                                                         178                                                                               10.2 (−0.4, 20.8)     184          178          11.7 (1.3, 22.1)
   Success                                                   119 (64.7)                                                  97 (54.5)                                                                                               127 (69.0)   102 (57.3)   
   Failure                                                   54 (29.3)                                                   73 (41.0)                                                                                               46 (25.0)    68 (38.2)    
   Indeterminate                                             11 (6.0)                                                    8 (4.5)                                                                                                 11 (6.0)     8 (4.5)      
  Secondary endpoint---clinical endpoint response                                                                                                                                                                                                          
  Clinical response, N                                       184                                                         178                                                                                                     NA           NA           NA
   Cure                                                      167 (90.8)                                                  163 (91.6)                                                                        −0.8 (−7.2, 5.6)                                
   Failure                                                   9 (4.9)                                                     12 (6.7)                                                                                                                          
   Indeterminate                                             8 (4.3)                                                     3 (1.7)                                                                                                                           
  Secondary endpoint---microbiological endpoint response                                                                                                                                                                                                   
  N                                                          184                                                         178                                                                                                     184          178          
   Eradication                                               121 (65.8)                                                  100 (56.2)                                                                        9.6 (−1.0, 20.1)      130 (70.7)   107 (60.1)   10.5 (0.2, 20.8)
   Persistence                                               50 (27.2)                                                   69 (38.8)                                                                                               41 (22.3)    62 (34.8)    
   Indeterminate                                             13 (7.1)                                                    9 (5.1)                                                                                                 13 (7.1)     9 (5.1)      
  Overall response in patients with AP                                                                                                                                                                                                                     
  Overall response, N                                        99                                                          94                                                                                                      99           94           
   Success                                                   67 (67.7)                                                   62 (66.0)                                                                         1.7 (−12.6, 16.0)     71 (71.7)    62 (66.0)    5.8 (−8.3, 19.9)
   Failure                                                   25 (25.3)                                                   29 (30.9)                                                                                               21 (21.2)    29 (30.9)    
   Indeterminate                                             7 (7.1)                                                     3 (3.2)                                                                                                 7 (7.1)      3 (3.2)      
  Overall response in patients with cUTI                                                                                                                                                                                                                   
  Overall response, N                                        85                                                          84                                                                                                      85           84           
   Success                                                   52 (61.2)                                                   35 (41.7)                                                                         19.5 (3.5, 35.5)      56 (65.9)    40 (47.6)    18.3 (2.4, 34.1)
   Failure                                                   29 (34.1)                                                   44 (52.4)                                                                                               25 (29.4)    39 (46.4)    
   Indeterminate                                             4 (4.7)                                                     5 (6.0)                                                                                                 4 (4.7)      5 (6.0)      
  Overall response in patients with bacteremia at baseline                                                                                                                                                                                                 
  Overall response, N                                        19                                                          13                                                                                                      19           13           
   Success                                                   9 (47.4)                                                    5 (38.5)                                                                          8.9 (−32.3, 50.1)     9 (47.4)     5 (38.5)     8.9 (−32.3, 50.1)
   Failure                                                   7 (36.8)                                                    8 (61.5)                                                                                                7 (36.8)     8 (61.5)     
   Indeterminate                                             3 (15.8)                                                    0 (0)                                                                                                   3 (15.8)     0 (0)        
  Clinical response, N                                       19                                                          13                                                                                                      NA           NA           NA
   Cure                                                      15 (78.9)                                                   10 (76.9)                                                                         2.0 (−33.8, 37.8)                               
   Failure                                                   2 (10.5)                                                    3 (23.1)                                                                                                                          
   Indeterminate                                             2 (10.5)                                                    0 (0)                                                                                                                             
  Microbiological response, N                                19                                                          13                                                                                1.2 (−40.5, 42.9)     NA           NA           NA
   Eradication                                               9 (47.4)                                                    6 (46.2)                                                                                                                          
   Persistence                                               6 (31.6)                                                    7 (53.8)                                                                                                                          
   Indeterminate                                             4 (21.2)                                                    0 (0)                                                                                                                             
  Estimated Charlson comorbidity index \<3                                                                                                                                                                                                                 
  Overall response, N                                        115                                                         107                                                                                                     NA           NA           NA
   Success                                                   85 (73.9)                                                   68 (63.6)                                                                         10.4 (−2.7, 23.4)                               
   Failure                                                   24 (20.9)                                                   32 (29.9)                                                                                                                         
   Indeterminate                                             6 (5.2)                                                     7 (6.5)                                                                                                                           
  Clinical response, N                                       115                                                         107                                                                                                     NA           NA           NA
   Cure                                                      106 (92.2)                                                  99 (92.5)                                                                         −0.3 (−8.2, 7.5)                                
   Failure                                                   4 (3.5)                                                     5 (4.7)                                                                                                                           
   Indeterminate                                             5 (4.3)                                                     3 (2.8)                                                                                                                           
  Microbiological response, N                                115                                                         107                                                                               8.5 (−4.5, 21.5)      NA           NA           NA
   Eradication                                               85 (73.9)                                                   70 (65.4)                                                                                                                         
   Persistence                                               22 (19.1)                                                   30 (28.0)                                                                                                                         
   Indeterminate                                             8 (7.0)                                                     7 (6.5)                                                                                                                           
  Estimated Charlson comorbidity index ≥3                                                                                                                                                                                                                  
  Overall response, N                                        69                                                          71                                                                                                      NA           NA           NA
   Success                                                   34 (49.3)                                                   29 (40.8)                                                                         8.4 (−9.4, 26.3)                                
   Failure                                                   30 (43.5)                                                   41 (57.7)                                                                                                                         
   Indeterminate                                             5 (7.2)                                                     1 (1.4)                                                                                                                           
  Clinical response, N                                       69                                                          71                                                                                                      NA           NA           NA
   Cure                                                      61 (88.4)                                                   64 (90.1)                                                                         −1.7 (−13.4, 9.9)                               
   Failure                                                   5 (7.2)                                                     7 (9.9)                                                                                                                           
   Indeterminate                                             3 (4.3)                                                     0                                                                                                                                 
  Microbiological response, N                                69                                                          71                                                                                9.9 (−8.0, 27.8)      NA           NA           NA
   Eradication                                               36 (52.2)                                                   30 (42.3)                                                                                                                         
   Persistence                                               28 (40.6)                                                   39 (54.9)                                                                                                                         
   Indeterminate                                             5 (7.2)                                                     2 (2.8)                                                                                                                           
  Prior antibiotic therapy category (no)                                                                                                                                                                                                                   
  Overall response, N                                        168                                                         169                                                                                                     168                       
   Success                                                   111 (66.1)                                                  91 (53.8)                                                                         12.2 (1.3, 23.2)      117 (69.6)   95 (56.2)    13.4 (2.6, 24.2)
   Failure                                                   46 (27.4)                                                   70 (41.4)                                                                                               40 (23.8)    66 (39.1)    
   Indeterminate                                             11 (6.5)                                                    8 (4.7)                                                                                                 11 (6.5)     8 (4.7)      
  Prior antibiotic therapy category (yes)                                                                                                                                                                                                                  
  Overall response, N                                        16                                                          9                                                                                                       16           9            
   Success                                                   8 (50.0)                                                    6 (66.7)                                                                          −16.7 (−64.7, 31.4)   10 (62.5)    7 (77.8)     −15.3 (−60.0, 29.5)
   Failure                                                   8 (50.0)                                                    3 (33.3)                                                                                                6 (37.5)     2 (22.2)     
  LFU (m-MITT)                                                                                                                                                                                                                                             
  Additional endpoint---clinical response at LFU                                                                                                                                                                                                           
  Clinical response, N                                       184                                                         178                                                                                                     NA           NA           NA
   Sustained clinical cure                                   159 (86.4)                                                  156 (87.6)                                                                        −1.2 (−8.7, 6.2)                                
   Relapse                                                   8 (4.3)                                                     7 (3.9)                                                                                                                           
   Clinical failure                                          9 (4.9)                                                     12 (6.7)                                                                                                                          
   Indeterminate                                             8 (4.3)                                                     3 (1.7)                                                                                                                           
  TOC (CE)                                                                                                                                                                                                                                                 
  Secondary endpoint---clinical endpoint response                                                                                                                                                                                                          
  Clinical response, N                                       199                                                         196                                                                                                     NA           NA           NA
   Cure                                                      188 (94.5)                                                  182 (92.9)                                                                        1.6 (−3.7, 6.9)                                 
   Failure                                                   11 (5.5)                                                    14 (7.1)                                                                                                                          
  TOC (ME)                                                                                                                                                                                                                                                 
  Secondary endpoint---clinical endpoint response                                                                                                                                                                                                          
  Clinical response, N                                       155                                                         145                                                                                                     NA           NA           NA
   Cure                                                      148 (95.5)                                                  135 (93.1)                                                                        2.4 (−3.5, 8.3)                                 
   Failure                                                   7 (4.5)                                                     10 (6.9)                                                                                                                          

The following subgroup analyses were planned a priori: overall, clinical, and microbiological response responses by infection type (AP or cUTI), bacteremia, and prior antibiotic therapy. Subgroup analyses that were not predefined and performed post hoc included: responses by systemic inflammatory response syndrome criteria and estimates Charlson comorbidity index category at baseline. Estimated Charlson comorbidity index predicts 10-year survival in patients with multiple comorbidities and is based on medical history information obtained at baseline. Charlson comorbidity index was categorized as \<3 and ≥3, and the numbers reported in this table are based on \<3 category. N: Percentages are calculated using N, the number of patients in the corresponding analysis population as the denominator. PFGE was performed to molecularly type all baseline and TOC pathogens (both treatment arms), in order to confirm microbiological eradication/persistence; a total of 20 postbaseline pathogens were identified as unique, unrelated strains compared to baseline. The primary efficacy endpoint was the proportion of patients with an overall success (clinical cure and microbiologic eradication) in the m-MITT population at the TOC visit. Secondary efficacy endpoints included proportion of patients with a response of clinical cure in the MITT, m-MITT and CE, and ME populations at TOC, and proportion of patients with a response of microbiologic eradication in the m-MITT and ME populations at TOC.

Abbreviations: AP, acute pyelonephritis; CE, clinical evaluable; CI, confidence interval; cUTI, complicated urinary tract infection; LFU, late follow-up; ME, microbiologic evaluable; m-MMIT, microbiologic modified intent-to-treat; NA, not applicable; PFGE, pulsed-field gel electrophoresis; PIP-TAZ, piperacillin-tazobactam; TOC, test of cure; ZTI-01, fosfomycin for injection.

^a^Treatment difference was the difference in the clinical cure rate between the 2 treatment groups (ZTI-01 -PIP-TAZ). The 95% CIs (2-sided) were computed using a continuity-corrected Z-statistic.

Post hoc analysis of the primary endpoint using microbiological eradication rates based on PFGE molecular typing revealed an increase in overall success in both treatment arms. Treatment difference in overall success at TOC between treatment groups further increased in favor of ZTI-01 (treatment difference 11.7%, 95% CI \[1.3, 22.1\]) ([Table 2](#T2){ref-type="table"}).

Secondary and Exploratory Efficacy Endpoints {#s14}
--------------------------------------------

Subgroup analyses of the primary endpoints ([Table 2](#T2){ref-type="table"}) were largely consistent across various baseline patient characteristics. Clinical cure rates were \>90% in both treatment groups at TOC in MITT, m-MITT, CE, and ME groups ([Table 2](#T2){ref-type="table"}).

Baseline cUTI/AP caused by a baseline pathogen that was resistant to PIP-TAZ was uncommon (14 ZTI-01 patients, 9 PIP-TAZ patients). Of the 9 PIP-TAZ patients infected with a PIP-TAZ-resistant pathogen, 33.3% were clinical cures compared with 78.6% of ZTI-01 treated patients (TOC, [Supplementary Appendix](#sup1){ref-type="supplementary-material"}). Among patients infected with a PIP-TAZ-susceptible uropathogen at baseline, overall success rates were similar to those observed in the primary endpoint analysis (TOC, 64.7% ZTI-01, 56.7% PIP-TAZ).

Microbiology {#s15}
------------

Most patients (92.4% ZTI-01, 94.4% PIP-TAZ, m-MITT) had a monomicrobial Gram-negative infection at baseline. Most common pathogens were *Escherichia coli* (72.3% ZTI-01, 74.7% PIP-TAZ) and *Klebsiella pneumoniae* (14.7% ZTI-01, 14.0% PIP-TAZ). All (100%) tested *E. coli* isolates in the ZTI-01 group were susceptible (provisional breakpoint MIC of ≤64 μg/mL), and 97.0% were susceptible to PIP-TAZ (MIC ≤16 μg/mL) (m-MITT).

Overall success (pathogens typed with PFGE analysis at TOC in m-MITT) occurred in 96/133 (72.2%) ZTI-01 and 77/133 (57.9%) PIP-TAZ patients who were infected with *E. coli* at baseline, and in 17/27 (63.0%) ZTI-01 and 13/25 (52.0%) PIP-TAZ patients who were infected at baseline with *K. pneumoniae*.

Clinical cure rates associated with *E. coli* and *K. pneumoniae* cUTI/AP were high and similar in both treatment groups ([Table 3](#T3){ref-type="table"}). Clinical cure rates in patients with severe disease (ie, met SIRS criteria or bacteremia) were high and similar between treatment groups ([Table 2](#T2){ref-type="table"}).

###### 

Clinical and Microbiological Outcomes by Baseline Pathogen at Test of Cure (Microbiologic Modified Intent-to-Treat, Post Hoc Pulsed-field Gel Electrophoresis Analysis^a^)

  Baseline Pathogen                                         Clinical Cure    Microbiologic Eradication                   
  --------------------------------------------------------- ---------------- --------------------------- --------------- ---------------
  *Escherichia coli*                                        120/133 (90.2)   120/133 (90.2)              97/133 (72.9)   84/133 (63.2)
  *Klebsiella pneumoniae*                                   25/27 (92.6)     25/25 (100)                 18/27 (66.7)    14/25 (56.0)
  *Proteus mirabilis*                                       8/9 (88.9)       3/5 (60.0)                  8/9 (88.9)      1/5 (20.0)
  *Enterobacter cloacae* species complex                    8/9 (88.9)       3/3 (100)                   6/9 (66.7)      3/3 (100)
  *Klebsiella oxytoca*                                      2/3 (66.7)       2/2 (100)                   2/3 (66.7)      2/2 (100)
  *Raoultella ornithinolytica*                              1/1 (100)        1/1 (100)                   1/1 (100)       1/1 (100)
  *Serratia marcescens*                                     1/1 (100)        1/1 (100)                   1/1 (100)       0/1 (0)
  *Morganella morganii*                                     0/0 (...)        1/1 (100)                   0/0 (...)       1/1 (100)
  *Citrobacter amalonaticus/farmer*                         1/1 (100)        0/0 (...)                   1/1 (100)       0/0 (...)
  *Pseudomonas aeruginosa*                                  8/8 (100)        9/9 (100)                   3/8 (37.5)      4/9 (44.4)
  *Acinetobacter baumannii-calcoaceticus* species complex   2/2 (100)        0/0 (...)                   2/2 (100)       0/0 (...)
  *Enterococcus faecalis*                                   2/3 (66.7)       6/7 (85.7)                  1/3 (33.3)      4/7 (57.1)
  *Staphylococcus aureus*                                   1/1 (100)        0/0 (...)                   1/1 (100)       0/0 (...)
  *Staphylococcus saprophyticus*                            0/0 (...)        1/1 (100)                   0/0 (...)       1/1 (100)

Percentages were calculated using N as the denominator, where N was the number of patients with the specified pathogens. If both a urine and blood sample had the same pathogen at baseline, eradication was defined as the baseline bacterial pathogen was reduced to \<10^4^ colony-forming unit/mL on urine culture and was negative on repeat blood culture.

Abbreviations: PIP-TAZ, piperacillin-tazobactam; ZTI-01, fosfomycin for injection.

^a^Pulsed-field gel electrophoresis was performed to molecularly type all baseline and test-of-cure pathogens (both treatment arms), in order to confirm microbiological eradication/persistence; a total of 20 postbaseline pathogens were identified as unique, unrelated strains compared to baseline.

Microbiologic eradication (PFGE-typed) occurred in 70.7% ZTI-01 versus 60.1% of PIP-TAZ patients (m-MITT) and 75.5% ZTI-01 versus 64.1% of PIP-TAZ patients (ME). Microbiological response rates varied between treatment groups among patients with severe disease; however, clinical cure rates in these subgroups were high and similar between treatment groups (TOC, [Table 2](#T2){ref-type="table"}).

Among patients with microbiological persistence at TOC, 14 patients (19.5% \[8/41\] ZTI-01, 9.7% \[6/62\] PIP-TAZ, TOC) had postbaseline growth of the baseline pathogen with ≥4-fold increase in MIC to study drug received; all had complicated disease, and 4 (3 ZTI-01, 1 PIP-TAZ) had recent or ongoing urinary tract instrumentation. A variety of pathogen species represented the isolates with ≥4-fold increase in MIC. Microbiological persistence rates associated with *Pseudomonas aeruginosa* were relatively high across the treatments (62.5% and 55.6%, respectively); however, each of these patients (8 ZTI-01, 9 PIP-TAZ patients) had explanations for *P. aeruginosa* persistence, including functional or anatomical abnormalities of the urinary tract (eg, atonic bladder, neurogenic bladder, hydronephrosis), indwelling instrumentation, and/or obstruction (eg, nephrolithiasis, stricture). Across either treatment, 100% of patients infected with *P. aeruginosa* were clinical cures (ie, requiring no further antibiotic), despite detection of *P. aeruginosa* persistence in postbaseline urine culture.

Overall, treatment arms were balanced in terms of number and type of baseline isolates bearing resistance characteristics (34%). Among these resistant isolates, clinical cure rates were high, and eradication rates numerically favored ZTI-01 ([Table 4](#T4){ref-type="table"}).

###### 

Clinical and Microbiologic Outcomes Among Patients With Baseline Pathogens Demonstrating Phenotypic Resistance Characteristics (Test of Cure, Microbiologic Modified Intent-to-Treat) \[[@CIT0009]\]

            ESBL         Amino-R      CRE          MDR                                                
  --------- ------------ ------------ ------------ ------------ ------------ ----------- ------------ ------------
  ZTI-01    93 (52/56)   55 (32/58)   97 (29/30)   67 (20/30)   100 (9/9)    56 (5/9)    92 (34/37)   54 (20/37)
  PIP-TAZ   93 (51/55)   47 (27/57)   94 (29/31)   38 (12/32)   85 (11/13)   31 (4/13)   90 (28/31)   36 (12/33)

Using minimum inhibitory concentrations from an accompanying antibiotic panel or agar dilution supplemented with glucose 6-phosphate for fosfomycin, blood or urine isolates were identified to assess patient and microbiologic outcome. The following definitions were used for this assessment---ESBL: ≥2 µg/mL MIC for aztreonam, ceftazidime, or ceftriaxone; CRE: ≥4 µg/mL imipenem or meropenem; Amino-R: gentamicin ≥8 µg/mL or amikacin ≥32 µg/mL; MDR: nonsusceptibility ≥3 classes, using definitions above plus levofloxacin ≥4 µg/mL and trimethoprim/sulfamethoxazole ≥32 g/mL. Patients could have more than 1 isolate from blood and/or urine sources, and all organisms are presented for completeness. Patients with multiple organisms were counted only once per resistance grouping. If the same species was identified from a different source, the isolate was counted once for microbiological outcome.

Abbreviations: CRE, carbapenem-resistant Enterobacteriaceae; ESBL, extended-spectrum beta-lactamase; MDR, multidrug-resistant; MIC, minimum inhibitory concentration; ZTI-01, fosfomycin for injection.

Safety {#s16}
------

A total of 42.1% ZTI-01 patients and 32.0% PIP-TAZ patients experienced at least 1 TEAE ([Table 5](#T5){ref-type="table"}). Most were mild or moderate in severity; severe TEAEs were uncommon (2.1% ZTI-01, 1.7% PIP-TAZ). Most common TEAEs in both treatment groups were asymptomatic laboratory abnormalities and gastrointestinal events. Serious AEs (SAEs) were uncommon in both treatment groups (2.1% ZTI-01, 2.6% PIP-TAZ). There were no deaths in the study; 1 SAE in each treatment group was deemed related to study drug (hypokalemia in a ZTI-01 patient, renal impairment in a PIP-TAZ patient). Study drug discontinuations due to TEAEs were infrequent and similar between treatment groups (3.0% ZTI-01, 2.6% PIP-TAZ).

###### 

Patients With Treatment-emergent Adverse Events (≥2% of Patients in Any Treatment Group) by System Organ Class and Preferred Term (Population: Safety)

  System Organ Class Preferred Term                      ZTI-01      PIP-TAZ
  ------------------------------------------------------ ----------- -----------
  Any AEs                                                99 (42.5)   74 (32.0)
  Any TEAEs                                              98 (42.1)   74 (32.0)
   Mild                                                  84 (36.1)   49 (21.2)
   Moderate                                              35 (15.0)   38 (16.5)
   Severe                                                5 (2.1)     4 (1.7)
  Drug-related TEAEs                                     48 (20.6)   32 (13.9)
  SAEs                                                   5 (2.1)     6 (2.6)
   Drug-related SAE                                      1 (0.4)     1 (0.4)
  TEAEs leading to study drug discontinuation            7 (3.0)     6 (2.6)
  Serious TEAEs leading to study drug discontinuation    0 (0)       1 (0.4)
  Gastrointestinal disorders                             25 (10.7)   17 (7.4)
   Nausea                                                10 (4.3)    3 (1.3)
   Diarrhea                                              9 (3.9)     11 (4.8)
   Vomiting                                              9 (3.9)     1 (0.4)
  General disorders and administration site conditions   14 (6.0)    14 (6.1)
   Infusion site phlebitis                               2 (0.9)     6 (2.6)
  Infections and infestations                            17 (7.3)    20 (8.7)
   Urinary tract infection                               4 (1.7)     5 (2.2)
  Investigations                                         20 (8.6)    8 (3.5)
   Alanine aminotransferase increased                    20 (8.6)    6 (2.6)
   Aspartate aminotransferase increased                  17 (7.3)    6 (2.6)
  Metabolism and nutrition disorders                     17 (7.3)    4 (1.7)
   Hypokalemia                                           15 (6.4)    3 (1.3)
  Nervous system disorders                               10 (4.3)    7 (3.0)
   Headache                                              6 (2.6)     5 (2.2)

Medical Dictionary for Regulatory Activities Version 19.0 was used to code TEAEs. Percentages were calculated using the number of patients in the safety population as the denominator. Treatment-emergent adverse events were defined as adverse events that newly appeared, increased in frequency, or worsened in severity following initiation of study drug. An adverse event was programmatically defined as treatment emergent if the start date and time was on or after the start date and time of the first dose of study drug.

Abbreviations: AE, adverse event; PIP-TAZ, piperacillin-tazobactam; SAE, serious adverse event; TEAE, treatment-emergent adverse event; fosfomycin for injection.

Most common laboratory abnormality TEAEs were increased ALT and AST ([Table 5](#T5){ref-type="table"}). None of the aminotransferase elevations were symptomatic or treatment-limiting. No patient met Hy's law criteria. All cases exhibiting ALT or AST \>3×ULN were adjudicated by an independent, blinded Transaminase Elevation Adjudication Committee; most ALT/AST elevations were deemed mild and possibly related to the study drug (23 ZTI-01, 5 PIP-TAZ cases).

Hypokalemia occurred in 71/232 (30.6%) ZTI-01 and 29/230 (12.6%) PIP-TAZ patients. Most cases were mild-to-moderate in severity; shifts in potassium levels from normal at baseline to hypokalemia were more frequent in the ZTI-01 group for mild (17.7% vs 11.3%), moderate (11.2% vs 0.9%), and severe (1.7% vs 0.4%) categories of hypokalemia. Hypokalemia was deemed a TEAE in 6.4% ZTI-01 and 1.3% PIP-TAZ, and all cases were transient and asymptomatic ([Table 5](#T5){ref-type="table"}). Although no significant cardiac AEs were observed, postbaseline QTcF of \>450 to ≤480 msec (baseline QTcF of ≤450 msec) occurred at a higher frequency in ZTI-01 patients (7.3%) compared with PIP-TAZ (2.5%). In the ZTI-01 arm, these appear to correlate with the hypokalemia associated with IV formulation salt load. Only 1 patient (PIP-TAZ group) had a baseline QTcF of ≤500 msec and postbaseline QTcF of \>500 msec.

DISCUSSION {#s17}
==========

In ZEUS, ZTI-01 was noninferior to PIP-TAZ in overall success for treatment of cUTI/AP. Overall success occurred in 64.7% of ZTI-01 and 54.5% of PIP-TAZ patients (treatment difference of 10.2%, 95% CI \[−0.4, 20.8\]). Post hoc analysis of this primary endpoint using PFGE-typed uropathogens demonstrated an increased treatment difference favoring ZTI-01 (69.0% ZTI-01 vs 57.3% PIP-TAZ patients, treatment difference of 11.7% \[95% CI: 1.3, 22.1\]). Clinical cure rates were \>90% in both treatment groups ([Table 2](#T2){ref-type="table"}). Microbiologic eradication rates at TOC (70.7% ZTI-01 vs 60.1% PIP-TAZ) were within range of those observed in contemporary cUTI trials, considering differences in timing of TOC, definitions of eradication, proportions of enrolled cUTI versus AP, instrumentation rates, and other factors \[[@CIT0010], [@CIT0011]\]. Most patients with microbiological persistence had identifiable reasons or risk factors for persistence. Notably, these patients were clinical cures at TOC, did not require rescue antimicrobial therapy, and remained sustained clinical cures at late follow-up. High dose of PIP-TAZ utilized in this study was according to current labeled guidelines for treating cUTI/AP \[[@CIT0008]\], and the dosage was similar to that used in a recent registration cUTI/AP study \[[@CIT0011]\].

Predominant uropathogens in both groups were *E. coli* and *K. pneumoniae* and are, in addition to other organisms recovered, representative of pathogens expected in US patients with cUTI/AP \[[@CIT0012]\]. Clinical cure rates at TOC were high for ZTI-01 (\>90%) for these 2 common pathogens, and microbiologic eradication rates were similar, 72.9% for *E. coli* and 66.7% for *K. pneumoniae*. Number of pathogens with ≥4-fold increase in MIC was low and similar between treatment groups. Main mechanism for the acquisition of fosfomycin resistance is impaired transport across the bacterial membrane, due to mutations of any of the target genes encoding antibiotic permeases (eg, glycerol-3-phosphate transporter and hexose-6-phosphate transporter in Enterobacteriaceae) \[[@CIT0013]\]. Despite wide use of IV fosfomycin outside the United States for \>40 years, resistance rates have remained low and stable \[[@CIT0014]\]. Fosfomycin resistance appears to carry a biological fitness cost, which may in part explain the low prevalence of resistance and the paradox of high rates of clinical cure despite increased MIC \[[@CIT0015]\].

Majority of TEAEs were mild or moderate in severity. The most common abnormal laboratory TEAEs were increased ALT, increased AST, and hypokalemia; these asymptomatic laboratory TEAEs occurred at higher frequencies in the ZTI-01 compared with the PIP-TAZ group, but none led to discontinuation of study drug. Aminotransferase elevation is a well-described AE of IV fosfomycin. In a recent review and analysis of the FDA AE reporting database (23 trials, N = 1242), the overall incidence of abnormal liver tests reported as AEs was approximately 1--2% among patients treated with various doses of IV fosfomycin (up to 24 g/day) \[[@CIT0016]\]. No cases of severe hepatotoxicity leading to liver failure, liver transplant, or death have been reported with IV fosfomycin. An independent hepatologist committee determined that all cases with ALT or AST increases \>3 × ULN were mild and asymptomatic, and no cases featured acute hypersensitivity, severe hepatotoxicity, or acute liver failure. In all cases, elevated aminotransferase values spontaneously returned to normal or baseline values after EOT. The clinical signature of ZTI-01-associated aminotransferase elevations is similar to that of other commonly used antibiotics.

Association of fosfomycin with abnormal electrolyte shifts (ie, hypokalemia and hypernatremia) is well described. Short fosfomycin infusions over 30 to 60 minutes, as were administered in this study, may be related to hypokalemia \[[@CIT0017]\]. Imbalance of hypokalemia between the ZTI-01 and PIP-TAZ groups in this study may also be explained by the higher sodium load of the ZTI-01 formulation; each gram of ZTI-01 contains 330 mg of sodium.

Limitations {#s18}
-----------

The ZEUS study design may not reflect standard management of cUTI/AP in the United States because it was designed to reflect regulatory requirements. For example, a fixed regimen of 7 days of IV therapy with hospitalization was mandated (or longer for bacteremic patients), and no oral switch therapy or combination antimicrobial therapy was allowed. However, this study design allowed for frequent safety assessments, which better defined the laboratory abnormalities associated with this antibiotic (including ALT/AST and electrolyte values). Certain patient groups were excluded from the study, including patients with end-stage renal disease (eg, requiring dialysis), immunocompromised patients, and patients with monomicrobial Gram-positive cUTI/AP. A majority of patients were enrolled outside the United States where higher rates of antimicrobial resistance are observed.

CONCLUSIONS {#s19}
===========

In this study, ZTI-01 met the primary objective of NI compared with PIP-TAZ in treatment of hospitalized patients with cUTI/AP. ZTI-01 provides a differentiated MOA with a broad spectrum of activity inclusive of Gram-negative pathogens, including ESBL producing and MDR Enterobacteriaceae. In the era of unmet medical needs due to growing concerns pertaining to MDR bacteria, ZTI-01 potentially offers an important novel IV therapeutic to the antibiotic armamentarium in the United States.

Supplementary Data {#s20}
==================

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

###### 

Click here for additional data file.
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